Introduction {#s02}
============

Epithelial--mesenchymal transition (EMT) is a developmental program that facilitates motility in otherwise adherent epithelial cells. During EMT, an epithelial cell sheds its connections to neighboring cells, converts from apico-basal to front-back polarity, and takes on the properties of a migratory mesenchymal cell ([@bib38]). Both EMT and its reverse process, mesenchymal--epithelial transition (MET), occur throughout development, wound healing, fibrosis, and tumor progression. During embryogenesis, EMT is required for gastrulation, the stage at which epithelial epiblast-derived cells ingress and transition into mesenchymal cells, forming the three germ layers ([@bib13]). At the onset of gastrulation, fibroblast growth factor signaling in the primitive streak activates the EMT- transcription factor (TF) *Snail* (*SNAI1*), which in turn transcriptionally represses E-cadherin, resulting in EMT ([@bib74]). A similar paradigm plays out repeatedly through development: EMT also occurs during neural crest cell migration ([@bib22]), somitogenesis ([@bib26]), and cardiac valve formation ([@bib100]). In adult organisms, facets of the EMT program are activated in response to cutaneous injury to facilitate collective migration. Keratinocytes at the edge of the wound respond to epidermal growth factor and TGF-β signaling to activate the EMT-TF *Slug* (*SNAI2*), which promotes motility and wound closure ([@bib42]). EMT also occurs in pathological conditions, including fibrosis and cancer. In chronic pulmonary obstructive disease, chronic inflammation leads to small-airway fibrosis that appears to be driven by the EMT of bronchial epithelial cells ([@bib51]). Similarly, EMT of alveolar epithelial cells has been reported as the source of myofibroblasts in idiopathic pulmonary fibrosis ([@bib55]). Likewise in the kidney, tubular epithelial cells undergo EMT to contribute to renal fibrosis ([@bib49]). Finally, EMT plays a significant role in tumor progression, where it has been implicated in many of the hallmarks of cancer ([@bib43]), particularly metastasis. This review discusses the evolving definition of EMT in the context of cancer as well as its functional consequences.

Characteristics and functional consequences of cancer EMT {#s03}
=========================================================

Since EMT enhances cellular mobility, it is no surprise that it has been connected to the dissemination of tumor cells. Indeed, carcinomas often lose epithelial markers or express EMT markers at the invasive front ([@bib10]; [@bib107]; [@bib52]; [@bib81]; [@bib61]) and in circulating tumor cells ([@bib6]; [@bib47]; [@bib62]), which represent the first steps of the metastatic cascade (invasion and intravasation, respectively). Expression of EMT-TFs correlates with poor clinical outcomes in cholangiocarcinoma, gastric cancer, and breast cancer, among others ([@bib88],[@bib89]; [@bib50]). This is in part due to EMT's role in promoting metastasis, which will be discussed in detail in a later section; however, it should be noted that while the primary consequence of EMT is increased motility, the phenomenon is also associated with stemness, therapy resistance, and immune evasion.

The connection between EMT and stem cell properties was first reported in a study by [@bib69], which demonstrated that mammary epithelial cells and breast cancer cells that have undergone EMT exhibit stem cell markers (CD44^hi^/CD24^lo^) and functional characteristics. When EMT was induced through treatment with TGF-β or overexpression of EMT-TFs, the cells formed more mammospheres (an in vitro test for self-renewal) and had an increased ability to repopulate a cleared mammary fat pad (in the case of normal mammary epithelial cells) or form tumors (in the case of breast cancer cells; [@bib69]). Similarly, in prostate cancer, EMT was accompanied by an increase in the expression of embryonic stem cell markers as well as an enhanced ability to form spheres in vitro and tumors in vivo ([@bib56]). In a mouse model of breast cancer recurrence, Snail-driven EMT promoted the regrowth of tumors ([@bib72]), and in patients, residual breast tumors left behind after conventional therapy often exhibit EMT and stem cell features ([@bib25]). Thus, in addition to stemness (or perhaps because of stemness), EMT is strongly associated with therapy resistance. Tumor cells selected for chemoresistance acquire an EMT phenotype ([@bib90]); conversely, tumor cells that are induced to undergo EMT acquire resistance to chemotherapy ([@bib117]), and inhibition of EMT can increase drug sensitivity ([@bib85]; [@bib34]; [@bib122]). EMT-TFs confer chemo- and radioresistance through a number of molecular mechanisms, including resistance to apoptosis, enhanced DNA damage repair and altered drug metabolism ([@bib105]).

With the advent of cancer immunotherapy, it has become apparent that EMT also protects tumor cells from immune cell--mediated killing. The first clue was the finding that SNAIL-induced EMT promotes melanoma metastasis by induction of regulatory T cell--mediated immunosuppression ([@bib60]). Cancer cells that undergo EMT secrete cytokines such as TGF-β, IL-10, and thrombospondin-1 that result in a generally immunosuppressive tumor microenvironment ([@bib113]). Breast cancer cell lines that skew mesenchymal recruit more immunosuppressive T regulatory cells and M2-polarized macrophages and fewer effector and cytotoxic T cells compared with epithelial lines when implanted into an immunocompetent host; moreover, tumors derived from the mesenchymal cell lines are resistant to anti-cytotoxic T lymphocyte--associated protein 4 (CTLA4) immunotherapy ([@bib30]). EMT has been associated with resistance to cytotoxic T lymphocyte killing due to the interruption of the immunological synapse ([@bib5]). Another mechanism of EMT-related immune escape is the up-regulation of immune checkpoint proteins on tumor cells such as programmed death ligand-1 (PD-L1), PD-L2, and B7-H3 ([@bib19]; [@bib68]; [@bib77]). With a hand in seemingly every aspect of tumor progression, EMT is a formidable obstacle in the treatment of cancer.

Molecular mechanisms of EMT {#s04}
---------------------------

Many developmental signal transduction pathways are capable of inducing EMT, including the TGF-β, epidermal growth factor, fibroblast growth factor, hepatocyte growth factor, Wingless/integrated, Sonic hedgehog, and Notch pathways ([@bib66], [@bib65]; [@bib70]; [@bib54]; [@bib100]). Cytokines such as IL-8, IL-6, and TNF-α, often secreted by tumor stroma, can also promote EMT ([@bib98]; [@bib111]; [@bib33]). Tumor cell interactions with extracellular matrix components can also induce EMT. For example, ovarian and prostate cancer cell lines that come into contact with type I collagen up-regulate EMT-TFs Snail and Slug ([@bib21]). Moreover, EMT programs can be activated through mechanotransduction: matrix stiffness, fluid flow, osmotic pressure, and tissue tension all influence the EMT status of cancer cells ([@bib71]). In the context of breast cancer, dense collagen fibrils increase matrix stiffness, which in turn promotes the nuclear translocation of the EMT-TF Twist1 (TWIST1; [@bib109]).

But how do epithelial cells respond to these extracellular signals to achieve the dramatic changes necessary to become motile? At the molecular level, cells going through EMT must repress epithelial genes that contribute to cellular adhesion (adherens junctions, tight junctions, and desmosomes), allowing them to detach from their neighbors. The classic epithelial marker E-cadherin (*CDH1*), a critical component of the adherens junction, is the most prominent target of repression during the EMT process. A number of EMT-TFs including Snail, Slug, and Zinc-finger E-box binding homeoboxes 1 and 2 (ZEB1/2) directly target *CDH1* and other epithelial genes for transcriptional repression ([@bib12]; [@bib24]; [@bib9]; [@bib94]). EMT-TFs themselves are repressed by epithelial-associated proteins such as ELF5, TFs Grainyhead-like 2 (GRHL2), and Ovo-like zinc fingers 1 and 2 (OVOL1/2), which help maintain an epithelial phenotype and can drive MET ([@bib15]; [@bib23]; [@bib87]). EMT-TFs are also negatively regulated by micro-RNAs (miRNAs), including miR-34, which represses *SNAI1,* and the miR-200 family, which represses *ZEB1* ([@bib11]; [@bib39]; [@bib57]; [@bib79]; [@bib95]). The balance between EMT-TFs and their antagonistic miRNAs plays a critical role in determining where a cell falls on the EMT spectrum as well as its potential for plasticity and metastasis ([@bib14]).

A cell undergoing EMT must also activate mesenchymal genes to promote the morphological and behavioral transformations necessary to become migratory. EMT-TFs Twist (TWIST1) and Pair related homeobox 1 (PRRX1) are strong promoters of the mesenchymal transcription program ([@bib114]; [@bib78]). Although the Snail and Zeb families of EMT-TFs were originally thought to act only as transcriptional repressors, it has been demonstrated that they can also act as transcriptional activators in certain contexts ([@bib110]; [@bib84]; [@bib63]). EMT-TFs promote the expression of crucial mesenchymal genes such as *vimentin* (*VIM*), *N-cadherin* (*CDH2*), *fibronectin* (*FN1*), and *fibroblast-specific protein 1* (*FSP1*). These downstream mesenchymal targets reshape the cytoskeleton and cell membrane to allow for migration.

Beyond transcriptional control of EMT {#s05}
-------------------------------------

Despite the intense focus within the field on EMT-TFs, it has become increasingly apparent that the mechanisms behind this process are not limited to the transcriptional level. EMT is facilitated through many levels of regulation, from epigenetic to posttranslational modifications and every step in between ([Fig. 1](#fig1){ref-type="fig"}). DNA methylation of the *CDH1* promoter is one mechanism of E-cadherin repression: ZEB1 interacts with DNA methyltransferase 1 (DNMT1) to accomplish this ([@bib36]). EMT-TFs can also recruit histone-modifying enzymes, including the histone demethylase LSD1, histone deacetylases HDAC1/2, and the polycomb repressive complex (PRC2), to repress the *CDH1* promoter ([@bib44]; [@bib108]; [@bib67]; [@bib1]; [@bib96]). At the RNA level, alternative splicing by Epithelial splicing regulatory proteins 1 and 2 (ESRP1/2), RNA binding motif protein 47 (RBM47), Quaking, RNA binding fox-1 homologue 2 (RBFOX2), and Muscleblind-like splicing regulator 1 (MBNL1) play a role in regulating EMT. ESRP1/2 and RBM47 promote epithelial-specific splicing, while the latter proteins promote mesenchymal-specific splicing ([@bib91]; [@bib106]; [@bib115]; [@bib75]). At the posttranscriptional level, besides miRNAs, long noncoding RNAs (lncRNAs) also contribute to EMT regulation. For example, lncRNA-activated by TGF-β (lncRNA-ATB) and lncRNA-PNUTS have been suggested to act as sponges for the miR-200 family and miR-205, respectively, sequestering these miRNAs to prevent them from inhibiting EMT-TF transcripts ([@bib118]; [@bib40]). Another EMT-promoting lncRNA, translational regulator lncRNA, negatively regulates the translation of *CDH1* mRNA ([@bib41]; [@bib28]). Similarly, cytoplasmic polyadenylation element binding protein 1 (CPEB1) promotes the shortening of the polyA tail of matrix metalloprotease 9 (MMP9), which reduces its translation; upon deletion of CPEB1, mammary tumor cells undergo EMT and become more metastatic ([@bib73]). In contrast, embryonic lethal abnormal vision--like RNA binding protein 1 (ELAVL1 or HUR) promotes EMT by stabilizing *Snai1* mRNA ([@bib123]). Posttranslational regulation of EMT-TFs is also an important level of control. SNAI1 and TWIST1 can be acetylated by p300, which modulates their stability, localization, and interactions with other proteins ([@bib93]; [@bib16]). SNAI1, SNAI2, TWIST1, and ZEB1 can also be phosphorylated, which affects their stabilization/degradation. Glycogen synthase kinase 3 β (GSK3β) and PKD1 phosphorylate Snail and Slug to promote their degradation, while MAPKs and Ataxia-Telangiesctasia mutated serine/threonine kinase phosphorylate TWIST1 and ZEB1, respectively, to stabilize them ([@bib8]; [@bib45]; [@bib53]; [@bib119]; [@bib121]). ZEB1 is regulated by the E3 ubiquitin ligase SIAH as well, which marks it for degradation ([@bib17]). Epithelial proteins can likewise be posttranslationally regulated during EMT. The E3 ubiquitin ligase Hakai ubiquitinates E-cadherin, inducing its endocytosis and destruction ([@bib35]). During hepatocyte growth factor--mediated EMT, E-cadherin can be phosphorylated by PKCδ, which disrupts its interaction with β-catenin on the cytoplasmic side and with E-cadherin on adjacent cells ([@bib18]). The E-cadherin protein also contains four asparagine (Asn) residues that are *N*-glycosylated, two of which are critical to its adhesive function: site-directed mutagenesis of Asn-554 and Asn-566 significantly reduced adhesion and enhanced the migratory ability of a breast cancer cell line ([@bib120]). EMT is a tightly regulated process because the consequences of an aberrant transition are significant, especially in the context of cancer.

![**Layers of EMT regulation.** EMT is regulated at the epigenetic, transcriptional, posttranscriptional, translational, and posttranslational levels. EMT-TFs recruit DNA methylation and histone modification machinery to stably repress epithelial genes and prevent their transcription. They are opposed by epithelial-associated TFs, which in turn repress EMT-TFs. Both epithelial and mesenchymal transcripts are alternatively spliced and regulated by miRNAs and lncRNAs. Translation initiation, mRNA stability, and polyadenylation affect the translation rate of epithelial and mesenchymal transcripts. Posttranslational modifications such as ubiquitylation, acetylation, and phosphorylation determine the balance between stability and degradation of epithelial and mesenchymal proteins.](JEM_20181827_Fig1){#fig1}

EMT/MET model of metastasis {#s06}
===========================

The EMT/MET model of metastatic dissemination attempts to reconcile the seemingly contradictory observation that metastatic lesions tend to have epithelial features, much like the primary tumor they arose from, but epithelial cells are not inherently invasive. The model postulates that cancer cells of epithelial origin undergo EMT to achieve the first steps of the metastatic cascade, including invasion into the tumor stroma, intravasation, and possibly extravasation at distant organs; however, in order to successfully form secondary tumors, cancer cells must undergo the reverse process of MET after reaching the metastatic site. Just like EMT, which is often induced by factors produced by stromal cells at the invasive front, MET is often an active process stimulated by molecular cues from metastatic niches in secondary organ sites ([@bib37]; [@bib27]; [@bib32]). While there is strong support in the literature for the role of EMT/MET in metastasis, the model continues to be challenged and updated with new research findings. This section presents results from these studies and synthesizes competing views for the EMT/MET model of metastasis.

EMT occurs during the natural history of tumor progression {#s07}
----------------------------------------------------------

The first challenge for the EMT/MET model was the difficulty in identifying tumor cells that had undergone EMT in vivo. Pathologists had long noted the mesenchymal morphology of what seemed to be cancer cells at the invasive front of tumors, but the origin of those cells was unclear because a mesenchymal tumor cell is for the most part indistinguishable from a mesenchymal stromal cell. However, with integration of the lineage labeling technique into the cancer field, it became possible to detect tumor cells that had undergone EMT spontaneously in vivo. The first direct evidence for EMT in breast cancer was reported by [@bib103]. In this study, *whey acidic protein (Wap)*--Cre was used to genetically label mammary epithelial cells with LacZ. These strains were crossed to three murine models of breast cancer: *Wap-myc*, mouse mammary tumor virus (*MMTV*)--*neu*, and *MMTV-polyoma middle T antigen* (*PyMT*). In *Wap*-Cre/*Wap-myc* tumors, LacZ^+^ cells could be found in the stroma (i.e., cells of epithelial origin that acquired mesenchymal characteristics); however, this was not seen in *MMTV-neu* or *MMTV-PyMT* tumors, suggesting that EMT occurs in Myc-driven metastasis but not in Neu- or PyMT-induced metastasis ([@bib103]). [@bib86] used a similar method to demonstrate that pancreatic cells of epithelial origin undergo EMT and disseminate not only in the context of cancer but even at the preneoplastic stage. In this study, a *YFP* genetic label was used in conjunction with the *Kras^G12D^/p53^fl/+^/Pdx1*-Cre mouse model (KPCY) of pancreatic ductal adenocarcinoma (PDAC) to show that tumor cells with mesenchymal features can be found in the primary tumor stroma, circulation, and metastatic sites ([@bib86]). Upon careful inspection of disseminated tumor cells in the liver of this mouse model, it was revealed that EMT features are predominant in small metastatic lesions, but large lesions tend to have epithelial characteristics, consistent with an EMT-to-MET switch ([@bib2]).

EMT is a driver of metastasis {#s08}
-----------------------------

While these reports are suggestive that EMT and MET are important for metastasis, they do not address whether either is necessary and sufficient for this process. [@bib104] elegantly demonstrated that *Twist1*-mediated EMT in squamous cell carcinoma was sufficient to drive dissemination, but *Twist1* had to be down-regulated at metastatic sites for colonization to occur. Using a doxycycline-inducible *Twist1* construct to induce EMT at the primary site either locally (by topical application) or systemically (by oral administration), the authors showed that *Twist1* expression (and thus EMT) drove dissemination. However, metastatic colonization occurred only in mice that had locally activated *Twist1*, which could be reversed at metastatic sites that were not exposed to doxycycline ([@bib104]). Similarly, *Snail* expression is sufficient to drive breast cancer cells into the circulation, but it must be down-regulated once those cells reach the lung in order for the cells to successfully colonize ([@bib102]). Along those lines, [@bib99] determined that isoform switching of *Prrx1* from the EMT-promoting *Prrx1b* to the MET-promoting *Prrx1a* is necessary for liver metastasis in pancreatic cancer. Likewise, EMT driven by loss of *p120-catenin* accelerates pancreatic tumor progression and distant metastasis; however, p120-catenin--mediated stabilization of E-cadherin (and therefore MET) is required for metastatic colonization of the liver ([@bib83]). Interestingly, experimental lung metastasis did not require restoration of p-120 catenin, suggesting that MET is not required in this context. Along similar lines of inquiry into the requirements of EMT and MET for metastasis, [@bib101] deleted it in β cells of a mouse model of neuroendocrine cancer to determine whether loss of the miR-200 family is sufficient to drive metastasis. The authors found that although mir-200 ablation increased survival, the resulting tumors metastasized more frequently, presumably due to increased EMT. The authors also deleted the miR-200 sites within the *Zeb1* 3′ untranslated region to promote EMT and found that this model phenocopies miR-200 ablation. Similar results were also seen in the KPC mouse model of PDAC with miR-200 deletion ([@bib101]). While suppression of the miR-200 family can promote dissemination, it is also an important driver of metastatic colonization. In addition to suppressing Zebs, the miR-200s target *Sec23 homologue A* (*Sec23a*), a gene important for the secretion of metastasis-suppressive proteins such as Tinagl1 ([@bib92]). Through this dual mechanism, ectopic expression of the miR-200 family suppresses tumor migration and invasion but promotes lung colonization ([@bib58]). These studies demonstrate that EMT drives dissemination and MET is necessary for metastatic colonization.

Context-dependent requirement of EMT for metastasis {#s09}
---------------------------------------------------

To address the question of whether EMT is required for metastasis, [@bib122] generated *Snail* and *Twist* knockout mice on the background of the *Kras^G12D^/p53^R172H/+^/Pdx1-*Cre (KPC) PDAC model. Surprisingly, neither *Snail* nor *Twist* deletion resulted in a significant decrease in metastasis, suggesting that EMT is not required for pancreatic cancer metastasis ([@bib122]). However, a similar study in which *Zeb1 was* deleted in the same mouse model reported a significant reduction in metastasis, reinvigorating the debate over whether EMT is required for metastasis ([@bib59]). *Snail* does seem to be critical for breast cancer metastasis, however, as conditional deletion of *Snail* in the context of the *MMTV-PyMT* model significantly reduced lung metastasis ([@bib102]). On the other hand, a report that used lineage labeling called into question the role of EMT in breast cancer metastasis. [@bib34] used *Fsp1*-Cre to genetically label *MMTV-PyMT* breast cancer cells that undergo Fsp1-mediated EMT with GFP and found that most lung metastases did not express GFP, suggesting that EMT is not required in this context ([@bib34]). Similarly, an EMT lineage label driven by either *α-smooth muscle actin*--Cre or *Fsp1*-Cre was not activated in macrometastatic lesions in an Flp-FRT mouse model of PDAC ([@bib20]). However, the results of these two studies contradict an earlier report that used an *Fsp1* knock-in GFP reporter and suicide construct (*thymidine kinase*) on an *MMTV-PyMT* background ([@bib112]). The resulting metastatic lesions contained cells that were double positive for the mammary cell marker casein and GFP, suggesting that EMT occurred during tumor progression. Moreover, replacement of endogenous *Fsp1* with GFP or ablation of FSP1^+^ cells with the nucleoside analogue ganciclovir both significantly abrogated lung metastasis. Thus, evidence supporting or arguing against an essential role of EMT in metastasis have been presented in different studies ([Table 1](#tbl1){ref-type="table"}); however, looking at the question from a contextual perspective can shed some light on the issue.

###### Summary of evidence for/against EMT in metastasis

  Gene of interest   Approach                               Tumor type   Model       Result                                                                                        Reference
  ------------------ -------------------------------------- ------------ ----------- --------------------------------------------------------------------------------------------- -----------
  *Twist1*           Conditional/inducible overexpression   SCC          DMBA        Sufficient for dissemination but must be down-regulated at metastatic site                    [@bib104]
  *Snai1*            Inducible overexpression               BC           MMTV-Neu    Sufficient for dissemination but must be down-regulated at metastatic site                    [@bib102]
  *Prrx1a/b*         Inducible overexpression               PDAC         KPC         Isoform B is sufficient for dissemination but must switch with isoform A at metastatic site   [@bib99]
  *miR-200s*         Conditional KO                         PNET/PDAC    RT2/KPC     Sufficient to drive metastasis                                                                [@bib101]
  *Snai1*            Conditional KO                         BC           MMTV-PyMT   Critical for metastasis                                                                       [@bib102]
  *Snai1/Twist1*     Conditional KO                         PDAC         KPC         Dispensable for metastasis                                                                    [@bib122]
  *Zeb1*             Conditional KO                         PDAC         KPC         Critical for metastasis                                                                       [@bib59]
  *Fsp1*             Lineage tracing and cell ablation      BC           MMTV-PyMT   Labeled cells contribute to and are required for metastasis                                   [@bib112]
  *Fsp1*             Lineage tracing                        BC           MMTV-PyMT   Labeled cells did not contribute to metastasis                                                [@bib34]
  *Fsp1/αSMA*        Lineage tracing                        PDAC         KPF         Labeled cells did not contribute to metastasis                                                [@bib20]

BC, breast cancer; DMBA, 7,12-dimethylbenz(a)anthracene; KPF, *Kras*^G12D^/*p53*^FRT/+^ or p53^R172H/+^/*Pdx1*-Flp; Neu, rat *Errb2* transgene; PNET, pancreatic neuroendocrine tumor; RT2, Rip-Tag2; SCC, squamous cell carcinoma.

Context matters {#s10}
---------------

There does not appear to be a single unifying molecular definition of EMT, especially in the context of cancer. Carcinomas use diverse programs to achieve the same goal of generating migratory tumor cells with the capability to invade, metastasize, and evade therapy. Cells that have undergone EMT in different tumor types (sometimes even within the same tumor) may look similar morphologically but can have dramatically divergent gene expression profiles. This might explain the apparently incongruous results of the aforementioned studies of EMT's role in metastasis ([@bib64]; [@bib3]; [@bib116]). Context-dependent manifestations of the EMT program were recently covered in an excellent review that discusses the nonredundant functions of various EMT-TFs ([@bib97]). Of note, while *Twist* appears to be a critical EMT-TF in breast cancer ([@bib114]; [@bib69]), its role in PDAC EMT is not strongly supported ([@bib46]). Instead, *Zeb1* seems to the primary EMT-TF responsible for PDAC EMT, which would explain why its deletion significantly reduced EMT and metastasis ([@bib59]), whereas *Twist* deletion did not ([@bib122]). Likewise, while FSP1 is a reliable marker of EMT in the KPC model of PDAC ([@bib2]), its usefulness as an EMT marker in breast cancer varies by model ([@bib103]), which could explain why *Fsp1* lineage-labeled tumor cells could not be found in lung metastases ([@bib34]). Thus it is likely that inconsistent findings within the EMT/metastasis field are due to different requirements for EMT effectors depending on tumor type, or due to an incomplete or partial EMT phenotype that does not involve EMT-TFs.

Partial EMT {#s11}
-----------

Emerging evidence suggests that EMT is a spectrum, and cancer cells often fall somewhere between fully epithelial and fully mesenchymal ([@bib76]). Tumor cells rarely commit to full EMT except in rare cases such as in hereditary diffuse gastric cancer and hereditary lobular breast cancer, where germline *CDH1* mutations and subsequent epigenetic inactivation results in irreversible EMT ([@bib7]; [@bib31]). More often, tumor cells exhibit partial EMT, which could manifest as the coexpression of epithelial and mesenchymal markers or the loss of epithelial markers without gain of mesenchymal markers. Partial EMT appears to confer tumor cells with enhanced epithelial--mesenchymal plasticity, which is imperative for metastasis, tumor recurrence, and therapy resistance ([Fig. 2](#fig2){ref-type="fig"}). Therefore, it is critical to acknowledge and investigate the myriad ways tumor cells move through the EMT spectrum to address the issue in the clinic.

![**Partial EMT: Heterogeneity and functional consequences.** EMT is a spectrum of epithelial and mesenchymal phenotypes. Partial EMT, which typically involves a combination of epithelial and mesenchymal gene expression, facilitates cluster migration/dissemination, plasticity between epithelial and mesenchymal states, and even plasticity in cell fate (i.e., transdifferentiation to adipocytes).](JEM_20181827_Fig2){#fig2}

A recent study reported that a partial EMT phenotype was predominant in the KPCY mouse model of PDAC, especially in association with the classic subtype ([@bib4]). Using a lineage-labeling strategy, CDH1^+^ epithelial and CDH1^−^ mesenchymal tumor cells were isolated from autochthonous PDAC tumors and subjected to RNA sequencing, which revealed that in a majority of tumors, *Cdh1* mRNA was maintained in cells that had lost it at the protein level. In contrast to the common EMT mechanism of EMT-TFs transcriptionally repressing the epithelial program, epithelial proteins like CDH1 were internalized in RAB11^+^ recycling endosomes. This potentially results in a cell poised for MET: indeed, CDH1^−^ cells derived from tumors that undergo partial EMT were found to be more capable of generating CDH1^+^ cells compared with cells from tumors that typically undergo full EMT. Interestingly, partial EMT tumor cell lines engaged in collective migration in vitro and generated more circulating tumor clusters in vivo compared with full EMT tumor lines, which disseminated as single cells in vitro and in vivo. Moreover, a partial EMT phenotype was detected in a number of human pancreatic, breast, and colon cancer cell lines, suggesting that partial EMT is a common feature of carcinomas.

Single-cell RNA sequencing (scRNA-seq) is a powerful technique that overcomes the ambiguity of population transcriptomics. Recently, this method has been used to demonstrate the coexpression of both epithelial and mesenchymal genes at single-cell resolution during development and tumor progression, revealing that partial EMT occurs naturally in vivo. During murine organogenesis, scRNA-seq transcriptional profiling has identified intestine, liver, and lung cells with a partial EMT phenotype at embryonic day 9.5--11.5 ([@bib29]). These cells express epithelial markers, including *CDH1*, *EPCAM*, *claudins*, and *cytokeratins*, as well as mesenchymal markers *VIM*, *FN1*, and *SPARC*. Interestingly, partial EMT cells had very low expression of classic EMT-TFs (*SNAI1/2*, *ZEB1/2*, and *TWIST1/2*), which is consistent with the expression of epithelial genes but suggests alternative mechanisms for inducing mesenchymal transcription. Partial EMT cells were not observed in adult intestine, liver, or lung; therefore, they probably represent a transient population during development. [@bib29] also investigated two previously published scRNA-seq datasets in primary breast cancer and lung adenocarcinoma patient-derived xenografts for evidence of partial EMT and found tumor cells that coexpressed *VIM*, *FN1*, *EPCAM*, and *CDH1*. Whether tumor cells arrive at partial EMT the same way that cells do during organogenesis remains an open question. In the same vein, [@bib82] surveyed primary and metastatic head and neck squamous cell carcinomas (HNSCCs) using scRNA-seq and identified a subset of malignant cells with a partial EMT signature. These cells bore some classic features of EMT, including expression of *VIM,* TGFβ-induced (*TGFBI*), and extracellular matrix genes, but expression of EMT-TFs was notably low, and consequently, epithelial gene expression was maintained. Using TGFBI expression to isolate partial EMT cells from an HNSCC cell line, the authors demonstrated that partial EMT cells are invasive and highly plastic. In situ, partial EMT cells were found at the leading edge of tumors near cancer-associated fibroblasts. Moreover, the partial EMT signature correlated with a malignant basal HNSCC subtype and lymph node metastasis, suggesting that partial EMT promotes loco-regional invasion.

[@bib80] investigated the EMT spectrum in lineage-labeled primary murine skin and mammary tumors using a panel of cell surface markers to identify cells in intermediate EMT states. Using different combinations of the markers CD106, CD51, and CD61, the authors distinguished six populations within the YFP^+^/EPCAM^−^ (presumably mesenchymal) compartment located throughout the EMT spectrum. Immunostaining revealed that these populations all expressed the mesenchymal marker VIM but varied in their expression of the epithelial marker cytokeratin-14. scRNA-seq further demonstrated the heterogeneity of EMT features among the six EPCAM^−^ populations. Transplantation assays revealed that all EPCAM^−^ populations had higher tumor-initiating capacity compared with EPCAM^+^ cells, but in vitro experiments showed that they varied in plasticity. Tumor cells in the middle of the EMT spectrum exhibited the most plasticity (i.e., were able to generate cells of all six subpopulations after sorting). Interestingly, although cells with a partial EMT phenotype were readily able to disseminate hematogenously, they did not have an increased ability to colonize the lung, suggesting that factors besides MET contribute to metastatic ability in this context ([@bib80]). This study paints a picture of the remarkably heterogeneous nature of EMT within tumors and begs the question of how it is established.

[@bib48] recently demonstrated that the partial EMT state makes breast cancer cells conducive to transdifferentiation into adipocytes. In this study, combination treatment with rosiglitazone (a peroxisome proliferator-activated receptor-γ agonist to induce adipocyte differentiation) and trametinib (a kinase inhibitor to block TGF-β signaling) was sufficient to convert partial EMT breast cancer cells into benign, cell cycle--arrested adipocytes, significantly reducing lung metastasis ([@bib48]). This intriguing report raises the possibility that cancer cell plasticity, which seems to be at its peak during partial EMT, could be exploited therapeutically.

Perspectives and future directions {#s12}
==================================

EMT is a dynamic, highly regulated process that occurs during embryogenesis and tumor progression to endow epithelial cells with motility, stemness, and therapy resistance. Its role in metastasis has been hotly debated, with recent reports both refuting and supporting the requirement for EMT. This is likely due to context-dependent EMT mechanisms, but further investigation of EMT effectors will be necessary to clarify the situation. Partial EMT is emerging as a common manifestation of the EMT program in tumors and can bestow cancer cells with increased plasticity.

At this point, the EMT field has collected an impressive body of knowledge on the signals that can promote EMT as well as effector proteins and their regulators. However, it remains unclear under which contexts these molecular players are involved in the natural history of tumor progression. Considering the emerging evidence that tumor types vary widely in their requirements for EMT-TFs and effectors in order to undergo EMT (or partial EMT), a systematic investigation of the necessity for each EMT driver in different in vivo tumor models would significantly enhance our understanding of how EMT actually happens in a living tumor. Moreover, this information would inform future experiments to determine whether EMT is required for metastasis: a clearer picture of which EMT programs are active in a given tumor type will be critical to successfully block EMT or eliminate cells that have undergone EMT. Only then will it be possible to definitively answer the question of whether EMT is crucial for metastasis in different cancer types and subtypes.

In the context of cancer, full EMT is rarely achieved, but rather partial EMT is more common, with cancer cells falling along a spectrum of epithelial and mesenchymal traits. What are the molecular mechanisms that cause a cell to begin down the path to EMT and stop partway there? It probably depends on a combination of cell-autonomous and non--cell-autonomous factors: perhaps microenvironmental cues, the transcriptomic landscape of the cell, or chromatin accessibility (which could be attributed to the cell of origin). What are the functional consequences of partial EMT? Recent reports suggest it pushes cells toward collective migration, but how does partial EMT relate to other facets of the EMT program such as stemness? Recent studies also started to appreciate the importance of EMT dynamics in mediating its biological impact in stemness and metastasis ([@bib14]), an area that will benefit from systems and computational biology approaches of investigation. Epithelial--mesenchymal plasticity seems to be important for allowing tumor cells to adapt to their ever-changing microenvironment, whether they find themselves in a distant organ or bombarded with a new therapy. Partial EMT appears to bestow dramatic plasticity on tumor cells, giving them the ability to transdifferentiate into an entirely different cell type, according to one recent report ([@bib48]). Therapeutically targeting partial EMT, and thus cellular plasticity, could prove to be efficacious; however, the molecular mechanisms governing partial EMT must be parsed first.

EMT contributes to nearly all of the hallmarks of cancer and continues to be an attractive target for cancer therapy. However, because the reverse process of MET appears to be critical for metastatic colonization, there has been justifiable hesitation to translate EMT inhibitors into the clinic for fear of stabilizing micrometastases. Moreover, it would be a challenge to address the problem of intra- and intertumor variation in EMT mechanisms. Nevertheless, a thoughtfully designed anti-EMT therapy combined with chemo-, radio-, and/or immunotherapy could optimize treatment outcome. Potential anti-EMT strategies could include reversing EMT, directly targeting cells that have undergone EMT, or inducing transdifferentiation of EMT cells into a harmless cell type as undertaken in [@bib48]. Direct targeting of EMT tumor cells has proved challenging due to their general drug resistance and the difficulty of drugging TFs such as the EMT-TFs. Targeting the downstream effectors of EMT/MET or the overall plasticity of cancer cells might be a more precise alternative for therapeutic development. For example, Tinagl1 is a secreted metastasis-inhibitory protein that is down-regulated by miR-200s during MET. Therapeutic treatment with recombinant Tinagl1 reduces tumor progression and metastasis while avoiding the induction of EMT by targeting miR-200s directly ([@bib92]). Finally, the transdifferentiation strategy would be valuable at any stage, perhaps even more so in the context of metastasis, since these lesions are especially refractory to treatment ([@bib48]). These approaches should be combined with other established treatments for maximum effect. For example, since EMT is associated with immunosuppression, anti-EMT therapy could precede immunotherapy to sensitize the tumor to treatment. As the spectrum of EMT continues to be refined, hopefully novel druggable targets will be identified to augment current treatments.
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